International Journal of Cancer Management

Published by: Kowsar
Crossmark

Construction and Structural Assessment of Nanocapsule Containing HER2-MUC1 Chimeric Protein as a Candidate for a Vaccine Against Breast Cancer

Nastaran Behnaz ORCID 1 , Shohreh Zare Karizi ORCID 1 , Shahram Nazarian ORCID 2 , Rouhollah Kazemi ORCID 3 , Mohammad Javad Motamedi ORCID 3 , Mahdi Fasihi-Ramandi ORCID 4 and Jafar Amani ORCID 5 , *
Authors Information
1 Department of Genetics and Biotechnology, School of Biological Science, Varamin-Pishva Branch, Islamic Azad University, Varamin, Iran
2 Department of Biology, Faculty of Science, Imam Hossain University, Tehran, Iran
3 Green Gene Company, Tehran, Iran
4 Molecular Biology Research Center, Systems Biology and Poisonings Institute, Baqiyatallah University of Medical Sciences, Tehran, Iran
5 Applied Microbiology Research Center, Systems Biology and Poisonings Institute, Baqiyatallah University of Medical Sciences, Tehran, Iran
Article information
  • International Journal of Cancer Management: May 31, 2019, 12 (5); e66671
  • Published Online: May 20, 2019
  • Article Type: Research Article
  • Received: January 23, 2018
  • Revised: May 6, 2019
  • Accepted: May 8, 2019
  • DOI: 10.5812/ijcm.66671

How to Cite: Behnaz N, Zare Karizi S, Nazarian S, Kazemi R, Motamedi M J, et al. Construction and Structural Assessment of Nanocapsule Containing HER2-MUC1 Chimeric Protein as a Candidate for a Vaccine Against Breast Cancer, Int J Cancer Manag. 2019 ; 12(5):e66671. doi: 10.5812/ijcm.66671.

Abstract
Copyright © 2019, Author(s). This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Objectives
3. Methods
4. Results
5. Discussion
Acknowledgements
Footnotes
References
  • 1. Moelans CB, de Weger RA, Van der Wall E, van Diest PJ. Current technologies for HER2 testing in breast cancer. Crit Rev Oncol Hematol. 2011;80(3):380-92. doi: 10.1016/j.critrevonc.2010.12.005. [PubMed: 21273092].
  • 2. Hanisch FG, Muller S. MUC1: The polymorphic appearance of a human mucin. Glycobiology. 2000;10(5):439-49. doi: 10.1093/glycob/10.5.439. [PubMed: 10764832].
  • 3. Norum LF, Sauren AM, Rye PD, Nustad K. New immunoassays for MUC1 in breast cancer. Tumour Biol. 2001;22(4):216-22. doi: 10.1159/000050619. [PubMed: 11399946].
  • 4. Ludovini V, Gori S, Colozza M, Pistola L, Rulli E, Floriani I, et al. Evaluation of serum HER2 extracellular domain in early breast cancer patients: Correlation with clinicopathological parameters and survival. Ann Oncol. 2008;19(5):883-90. doi: 10.1093/annonc/mdm585. [PubMed: 18187484].
  • 5. Soybir GR. Nonepithelial malignancies of the breast. In: Aydiner A, Igci A, Soran A, editors. Breast disease. Switzerland: Springer; 2016. p. 429-43.
  • 6. Ross JS, Slodkowska EA, Symmans WF, Pusztai L, Ravdin PM, Hortobagyi GN. The HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized medicine. Oncologist. 2009;14(4):320-68. doi: 10.1634/theoncologist.2008-0230. [PubMed: 19346299].
  • 7. Gheybi E, Salmanian AH, Fooladi AAI, Salimian J, Hosseini HM, Halabian R, et al. Immunogenicity of chimeric MUC1-HER2 vaccine against breast cancer in mice. Iran J Basic Med Sci. 2018;21(1):26-32. doi: 10.22038/IJBMS.2017.25686.6335. [PubMed: 29372033]. [PubMed Central: PMC5776432].
  • 8. Amani J, Mousavi SL, Rafati S, Salmanian AH. Immunogenicity of a plant-derived edible chimeric EspA, intimin and Tir of Escherichia coli O157:H7 in mice. Plant Sci. 2011;180(4):620-7. doi: 10.1016/j.plantsci.2011.01.004. [PubMed: 21421410].
  • 9. Sinha VR, Trehan A. Biodegradable microspheres for protein delivery. J Control Release. 2003;90(3):261-80. doi: 10.1016/S0168-3659(03)00194-9. [PubMed: 12880694].
  • 10. van der Lubben IM, Verhoef JC, Borchard G, Junginger HE. Chitosan for mucosal vaccination. Adv Drug Deliv Rev. 2001;52(2):139-44. doi: 10.1016/S0169-409X(01)00197-1. [PubMed: 11718937].
  • 11. De Magistris MT. Mucosal delivery of vaccine antigens and its advantages in pediatrics. Adv Drug Deliv Rev. 2006;58(1):52-67. doi: 10.1016/j.addr.2006.01.002. [PubMed: 16516335].
  • 12. Gheybi E, Amani J, Salmanian AH, Mashayekhi F, Khodi S. Designing a recombinant chimeric construct contain MUC1 and HER2 extracellular domain for prediagnostic breast cancer. Tumour Biol. 2014;35(11):11489-97. doi: 10.1007/s13277-014-2483-y. [PubMed: 25128064].
  • 13. Bollag DM, Rozycki MD, Edelstein SJ. Protein methods. New York: Wiley-Liss; 1996.
  • 14. Doavi T, Mousavi SL, Kamali M, Amani J, Fasihi Ramandi M. Chitosan-based intranasal vaccine against Escherichia coli O157:H7. Iran Biomed J. 2016;20(2):97-108. [PubMed: 26724233]. [PubMed Central: PMC4726890].
  • 15. Zhou J, Zhong Y. Breast cancer immunotherapy. Cell Mol Immunol. 2004;1(4):247-55.
  • 16. Esteva FJ, Hortobagyi GN. Prognostic molecular markers in early breast cancer. Breast Cancer Res. 2004;6(3):109-18. doi: 10.1186/bcr777. [PubMed: 15084231]. [PubMed Central: PMC400674].
  • 17. Fredenberg S, Wahlgren M, Reslow M, Axelsson A. The mechanisms of drug release in poly(lactic-co-glycolic acid)-based drug delivery systems-a review. Int J Pharm. 2011;415(1-2):34-52. doi: 10.1016/j.ijpharm.2011.05.049. [PubMed: 21640806].
  • 18. Tang Y, Wang L, Zhang P, Wei H, Gao R, Liu X, et al. Detection of circulating anti-mucin 1 (MUC1) antibodies in breast tumor patients by indirect enzyme-linked immunosorbent assay using a recombinant MUC1 protein containing six tandem repeats and expressed in Escherichia coli. Clin Vaccine Immunol. 2010;17(12):1903-8. doi: 10.1128/CVI.00142-10. [PubMed: 20876819]. [PubMed Central: PMC3008176].
  • 19. Mukhopadhyay P, Chakraborty S, Ponnusamy MP, Lakshmanan I, Jain M, Batra SK. Mucins in the pathogenesis of breast cancer: Implications in diagnosis, prognosis and therapy. Biochim Biophys Acta. 2011;1815(2):224-40. doi: 10.1016/j.bbcan.2011.01.001. [PubMed: 21277939]. [PubMed Central: PMC3230300].
  • 20. Daniele L, Sapino A. Anti-HER2 treatment and breast cancer: State of the art, recent patents, and new strategies. Recent Pat Anticancer Drug Discov. 2009;4(1):9-18. doi: 10.2174/157489209787002489. [PubMed: 19149684].
  • 21. Wilkie S, van Schalkwyk MC, Hobbs S, Davies DM, van der Stegen SJ, Pereira AC, et al. Dual targeting of ErbB2 and MUC1 in breast cancer using chimeric antigen receptors engineered to provide complementary signaling. J Clin Immunol. 2012;32(5):1059-70. doi: 10.1007/s10875-012-9689-9. [PubMed: 22526592].
  • 22. des Rieux A, Fievez V, Garinot M, Schneider YJ, Preat V. Nanoparticles as potential oral delivery systems of proteins and vaccines: A mechanistic approach. J Control Release. 2006;116(1):1-27. doi: 10.1016/j.jconrel.2006.08.013. [PubMed: 17050027].
  • 23. Zhao K, Li W, Huang T, Luo X, Chen G, Zhang Y, et al. Preparation and efficacy of Newcastle disease virus DNA vaccine encapsulated in PLGA nanoparticles. PLoS One. 2013;8(12). e82648. doi: 10.1371/journal.pone.0082648. [PubMed: 24386106]. [PubMed Central: PMC3873271].
  • 24. Pawar D, Jaganathan KS. Mucoadhesive glycol chitosan nanoparticles for intranasal delivery of hepatitis B vaccine: Enhancement of mucosal and systemic immune response. Drug Deliv. 2016;23(1):185-94. doi: 10.3109/10717544.2014.908427. [PubMed: 24825494].
  • 25. Tobio M, Sanchez A, Vila A, Soriano II, Evora C, Vila-Jato JL, et al. The role of PEG on the stability in digestive fluids and in vivo fate of PEG-PLA nanoparticles following oral administration. Colloids Surf B Biointerfaces. 2000;18(3-4):315-23. doi: 10.1016/S0927-7765(99)00157-5. [PubMed: 10915953].

Featured Image:

Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:

Author(s):

Article(s):

Create Citiation Alert
via Google Reader

Readers' Comments